TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Loss Per Share

Loss Per Share	12 Months Ended
Dec. 31, 2015
Earnings Per Share [Abstract]
Loss Per Share	Note 14 - Loss per share The calculation of basic and diluted loss per share at December 31, 2015 and 2014 was based on the loss attributable to common shareholders of $9,311,913 and $3,142,960. The basic and diluted weighted average number of common shares outstanding for 2015 and 2014 was 5,140,920 and 4,745,684. Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period. Potential common shares consist of options and warrants. Diluted net loss per common share was the same as basic net loss per common share for the years ended December 31, 2015 and 2014 since the effect of options and warrants would be anti-dilutive due to the net loss attributable to the common shareholders. Instruments excluded from dilutive earnings per share, because their inclusion would be anti-dilutive, were as follows: incentive and award stock options 220,500 for 2015 (2014: 175,000); warrants for 2015 (2014: 1,989).

Loss Per Share

12 Months Ended

Dec. 31, 2015

Note 14 - Loss per share

The calculation of basic and diluted loss per share at December 31, 2015 and 2014 was based on the loss attributable to common shareholders of $9,311,913 and $3,142,960. The basic and diluted weighted average number of common shares outstanding for 2015 and 2014 was 5,140,920 and 4,745,684.

Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period.

Potential common shares consist of options and warrants. Diluted net loss per common share was the same as basic net loss per common share for the years ended December 31, 2015 and 2014 since the effect of options and warrants would be anti-dilutive due to the net loss attributable to the common shareholders. Instruments excluded from dilutive earnings per share, because their inclusion would be anti-dilutive, were as follows: incentive and award stock options 220,500 for 2015 (2014: 175,000); warrants for 2015 (2014: 1,989).